Boston Scientific Co. (NYSE:BSX) Shares Bought by FourThought Financial LLC

FourThought Financial LLC raised its stake in Boston Scientific Co. (NYSE:BSX – Get Rating) by 40.6% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,604 shares of the medical equipment provider’s stock after acquiring an additional 1,041 shares during the period. FourThought Financial LLC’s holdings in Boston Scientific were worth $140,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Signaturefd LLC boosted its stake in Boston Scientific by 34.0% in the third quarter. Signaturefd LLC now owns 17,488 shares of the medical equipment provider’s stock valued at $677,000 after acquiring an additional 4,437 shares during the period. Wedmont Private Capital acquired a new position in Boston Scientific in the third quarter valued at approximately $335,000. Ieq Capital LLC boosted its stake in Boston Scientific by 48.3% in the third quarter. Ieq Capital LLC now owns 38,196 shares of the medical equipment provider’s stock valued at $1,480,000 after acquiring an additional 12,440 shares during the period. Personal Capital Advisors Corp boosted its stake in Boston Scientific by 28.5% in the third quarter. Personal Capital Advisors Corp now owns 10,225 shares of the medical equipment provider’s stock valued at $396,000 after acquiring an additional 2,265 shares during the period. Finally, Adirondack Trust Co. boosted its stake in Boston Scientific by 126.0% in the third quarter. Adirondack Trust Co. now owns 1,130 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 630 shares during the period. 90.23% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.7 %

Shares of NYSE:BSX opened at $47.95 on Friday. The stock has a market capitalization of $68.80 billion, a price-to-earnings ratio of 106.56, a PEG ratio of 2.28 and a beta of 0.79. Boston Scientific Co. has a 1-year low of $34.98 and a 1-year high of $48.87. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.02 and a current ratio of 1.51. The company has a 50 day moving average price of $46.86 and a 200 day moving average price of $44.21.

Boston Scientific (NYSE:BSX – Get Rating) last issued its earnings results on Wednesday, February 1st. The medical equipment provider reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.02). The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.24 billion. Boston Scientific had a return on equity of 14.29% and a net margin of 5.50%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 earnings per share. On average, research analysts anticipate that Boston Scientific Co. will post 1.9 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BSX has been the topic of a number of recent analyst reports. Raymond James lifted their price target on Boston Scientific from $54.00 to $56.00 and gave the company a “strong-buy” rating in a report on Thursday, February 2nd. Needham & Company LLC lifted their price target on Boston Scientific from $48.00 to $53.00 and gave the company a “buy” rating in a report on Thursday, February 2nd. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $48.00 to $55.00 and gave the company an “overweight” rating in a report on Thursday, February 2nd. Mizuho began coverage on shares of Boston Scientific in a research note on Thursday, December 22nd. They set a “neutral” rating and a $52.00 price objective on the stock. Finally, Stifel Nicolaus raised their price objective on shares of Boston Scientific from $50.00 to $52.00 in a research note on Wednesday, February 1st. One analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $51.50.

Insider Buying and Selling

In related news, EVP Arthur C. Butcher sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $48.74, for a total value of $1,315,980.00. Following the completion of the sale, the executive vice president now owns 23,392 shares in the company, valued at approximately $1,140,126.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Arthur C. Butcher sold 27,000 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $48.74, for a total value of $1,315,980.00. Following the completion of the sale, the executive vice president now owns 23,392 shares in the company, valued at approximately $1,140,126.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel J. Brennan sold 75,610 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $46.64, for a total transaction of $3,526,450.40. Following the completion of the sale, the chief financial officer now owns 255,958 shares of the company’s stock, valued at approximately $11,937,881.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 115,182 shares of company stock worth $5,432,674. Corporate insiders own 0.71% of the company’s stock.

About Boston Scientific

(Get Rating)

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Urology and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions.